Andrea Calcagno1, Ambra Barco2, Mattia Trunfio2, Stefano Bonora2. 1. Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, c/o Ospedale Amedeo di Savoia, C.so Svizzera 164, 10159, Turin, Italy. andrea.calcagno@unito.it. 2. Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, c/o Ospedale Amedeo di Savoia, C.so Svizzera 164, 10159, Turin, Italy.
Abstract
PURPOSE OF REVIEW: Neurocognitive disorders are not uncommon in HIV-positive patients but their pathogenesis is multifactorial and incompletely understood. After excluding contributing comorbidities, several factors may impair neurocognition including severe immune suppression, incomplete antiviral efficacy, drugs' persistent immune activation, vascular abnormalities, and drugs' neurotoxicity. The effectiveness of targeted antiretroviral strategies on these risk factors is unknown. RECENT FINDINGS: Recent studies support the idea that residual cerebrospinal fluid HIV RNA in the setting of plasma viral suppression is associated with compartmental immune activation but the link to neuronal damage is debated. Some authors have reported an incomplete antiviral efficacy in macrophage-derived cells but targeted antiretroviral regimen switches have not been performed. Additionally, improvements in neurocognition using drugs with better central nervous system penetration or maraviroc (associated with favorable immunological properties) have been observed in pilot studies. Trials evaluating specific interventions for cardiovascular health (including brain white matter abnormalities) and neurotoxicity of antiretrovirals are warranted. Central nervous system-targeted antiretroviral strategies are needed in patients with uncontrolled cerebrospinal HIV replication, and they may be suggested in subjects with low CD4 nadir, individuals carrying drug-resistant viruses, and those with compartmental immune activation.
PURPOSE OF REVIEW: Neurocognitive disorders are not uncommon in HIV-positivepatients but their pathogenesis is multifactorial and incompletely understood. After excluding contributing comorbidities, several factors may impair neurocognition including severe immune suppression, incomplete antiviral efficacy, drugs' persistent immune activation, vascular abnormalities, and drugs' neurotoxicity. The effectiveness of targeted antiretroviral strategies on these risk factors is unknown. RECENT FINDINGS: Recent studies support the idea that residual cerebrospinal fluid HIV RNA in the setting of plasma viral suppression is associated with compartmental immune activation but the link to neuronal damage is debated. Some authors have reported an incomplete antiviral efficacy in macrophage-derived cells but targeted antiretroviral regimen switches have not been performed. Additionally, improvements in neurocognition using drugs with better central nervous system penetration or maraviroc (associated with favorable immunological properties) have been observed in pilot studies. Trials evaluating specific interventions for cardiovascular health (including brain white matter abnormalities) and neurotoxicity of antiretrovirals are warranted. Central nervous system-targeted antiretroviral strategies are needed in patients with uncontrolled cerebrospinal HIV replication, and they may be suggested in subjects with low CD4 nadir, individuals carrying drug-resistant viruses, and those with compartmental immune activation.
Authors: Ronald J Ellis; Scott Letendre; Florin Vaida; Richard Haubrich; Robert K Heaton; Ned Sacktor; David B Clifford; Brookie M Best; Susanne May; Anya Umlauf; Mariana Cherner; Chelsea Sanders; Craig Ballard; David M Simpson; Cheryl Jay; J Allen McCutchan Journal: Clin Infect Dis Date: 2013-12-18 Impact factor: 9.079
Authors: Guillaume Martin-Blondel; David Brassat; Jan Bauer; Hans Lassmann; Roland S Liblau Journal: Nat Rev Neurol Date: 2016-01-18 Impact factor: 42.937
Authors: Thomas M Gates; Lucette A Cysique; Krista J Siefried; Joga Chaganti; Kirsten J Moffat; Bruce J Brew Journal: AIDS Date: 2016-02-20 Impact factor: 4.177
Authors: Robert S Hogg; Oghenowede Eyawo; Alexandra B Collins; Wendy Zhang; Shahab Jabbari; Mark W Hull; Viviane Dias Lima; Tareq Ahmed; Claire E Kendall; Keri N Althoff; Amy C Justice; Rolando Barrios; Jeannie Shoveller; Julio S G Montaner Journal: Lancet HIV Date: 2017-03-03 Impact factor: 12.767
Authors: Lewis J Haddow; Rosanna Laverick; Marina Daskalopoulou; Jeffrey McDonnell; Fiona C Lampe; Richard Gilson; Andrew Speakman; Andrea Antinori; Pietro Balestra; Tina Bruun; Jan Gerstoft; Lars Nielsen; Anna Vassilenko; Simon Collins; Alison J Rodger Journal: AIDS Behav Date: 2018-05
Authors: A Barco; S Orlando; G Stroffolini; V Pirriatore; A Lazzaro; D Vai; G Guastamacchia; G Noce; C Atzori; M Trunfio; S Bonora; G Di Perri; A Calcagno Journal: J Neurovirol Date: 2022-01-19 Impact factor: 2.643
Authors: Yang Qu; Andrea Weinstein; Zheng Wang; Yu Cheng; Lawrence Kingsley; Andrew Levine; Eileen Martin; Cynthia Munro; Ann B Ragin; Leah H Rubin; Ned W Sacktor; Eric C Seaberg; James T Becker Journal: AIDS Date: 2022-01-01 Impact factor: 4.177